Comprehensive analysis of Tata Nifty MidSmall Healthcare Index Fund-Reg (IDCW) (44782) providing detailed insights into fund performance, portfolio holdings, risk metrics, expense ratios, and investment recommendations.
Tata Asset Management Ltd
The investment objective of the scheme is to provide returns, before expenses, that are in line with the performance of Nifty MidSmall Healthcare Index (TRI), subject to tracking error. However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved. The scheme does not assure or guarantee any returns.
A comprehensive at-a-glance view of key mutual fund health indicatorsHover or click any card to view detailed metrics
Moderate Returns
High Risk
Moderate Expenses
Equity Focused
New Team
Average Quality
Showing 1Y NAV history
Performance across different time periods
Fund shows mixed signals. Consider your investment timeline and risk tolerance.
Review detailed analysis and consider dollar-cost averaging through SIPs.
Fund shows mixed signals. Consider your investment timeline and risk tolerance.
Review detailed analysis and consider dollar-cost averaging through SIPs.
Historical performance consistency
Outperformance vs benchmark
Market exposure level
Recent performance momentum
Fund management costs
Risk-adjusted returns
Fund manager experience
Assets under management
This fund has outperformed its benchmark by 0.38% over the 3Y period.
See how your money can grow and compare with popular investment options
Disclaimer: Returns are illustrative and based on assumed rates. Mutual fund investments are subject to market risk. Please read scheme documents carefully.
| Company | Sector | % Assets |
|---|---|---|
| Max Healthcare Institute Ltd | Healthcare | 15.01% |
| Lupin Ltd | Pharmaceuticals | 7.56% |
| Fortis Healthcare Ltd | Healthcare | 7.24% |
| Laurus Labs Ltd | Pharmaceuticals | 5.55% |
| Glenmark Pharmaceuticals Ltd | Pharmaceuticals | 5.21% |
| Aurobindo Pharma Ltd | Pharmaceuticals | 5.17% |
| Mankind Pharma Ltd | Pharmaceuticals | 4.70% |
| Alkem Laboratories Ltd | Pharmaceuticals | 4.39% |
| Biocon Ltd | Pharmaceuticals | 3.81% |
| Ipca Laboratories Ltd | Pharmaceuticals | 3.32% |
Compare against Index Fund category average
This comparison shows how the fund performs relative to the Index Fund category average. Positive values indicate outperformance, while negative values show underperformance.
Compare with similar funds in Index Fund category
| Fund Name | NAV | 3M | 6M | 1Y |
|---|---|---|---|---|
| Invesco India Nifty G-sec Sep 2032 Index Fund-Dir (IDCW) | ₹1230.12 | -1.03% | 4.26% | 8.39% |
| Invesco India Nifty G-sec Sep 2032 Index Fund-Dir (G) | ₹1230.12 | -1.03% | 4.26% | 8.39% |
| Invesco India Nifty G-sec Sep 2032 Index Fund-Reg (G) | ₹1225.70 | -1.07% | 4.18% | 8.23% |
| Invesco India Nifty G-sec Sep 2032 Index Fund-Reg (IDCW) | ₹1225.68 | -1.07% | 4.18% | 8.23% |
| Invesco India Nifty G-sec Jul 2027 Index Fund-Dir (G) | ₹1208.94 | 1.16% | 4.38% | 8.21% |
| Invesco India Nifty G-sec Jul 2027 Index Fund-Dir (IDCW | ₹1208.94 | 1.16% | 4.38% | 8.21% |
| Invesco India Nifty G-sec Jul 2027 Index Fund-Reg (IDCW) | ₹1204.58 | 1.13% | 4.31% | 8.05% |
| Invesco India Nifty G-sec Jul 2027 Index Fund-Reg (G) | ₹1204.56 | 1.13% | 4.31% | 8.05% |
| HDFC BSE Sensex Index Fund - Direct | ₹766.86 | 0.30% | 11.07% | -1.48% |
| HDFC BSE Sensex Index Fund - Regular | ₹748.57 | 0.26% | 10.99% | -1.63% |
A seasoned investment professional with over 1 years of experience in equity research and fund management. Known for consistent performance and a disciplined investment approach focused on quality growth stocks.